Intuitive Surgical (NASDAQ:ISRG) Director Sells $28,303.20 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amy Ladd sold 72 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $393.10, for a total transaction of $28,303.20. Following the transaction, the director directly owned 179 shares in the company, valued at approximately $70,364.90. The trade was a 28.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $401.27 on Friday. The firm has a fifty day simple moving average of $392.00 and a 200-day simple moving average of $441.60. The company has a market capitalization of $141.76 billion, a PE ratio of 45.96, a price-to-earnings-growth ratio of 2.90 and a beta of 1.46. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same quarter in the previous year, the firm posted $1.81 EPS. The firm’s quarterly revenue was up 18.4% on a year-over-year basis. Equities research analysts predict that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. The Goldman Sachs Group set a $558.00 price target on Intuitive Surgical in a research note on Wednesday, May 27th. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a research note on Tuesday, May 19th. Barclays set a $651.00 price objective on Intuitive Surgical and gave the stock an “overweight” rating in a report on Thursday, April 23rd. UBS Group began coverage on Intuitive Surgical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $500.00 target price on the stock. Finally, HSBC cut Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 target price for the company. in a research note on Thursday, July 30th. Twenty-two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $508.68.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Oppenheimer upgraded ISRG to Outperform with a $500 price target, arguing that Medtronic’s Hugo and Intuitive’s Ottava face workflow, operating-room space and adoption challenges that limit their near-term threat to the da Vinci franchise. Oppenheimer upgrade report
• Positive Sentiment: Bernstein reiterated its Buy rating and $685 target, citing progress on a new gastrointestinal platform, continued da Vinci 5 adoption and the company’s recurring instruments and service revenue model. Bernstein rating report
• Positive Sentiment: TCW Funds said Intuitive Surgical’s competitive moat remains intact despite near-term volatility. The ENCOMPASS study also highlights potential expansion of the Ion robotic platform into lung biopsy procedures, which could support future recurring revenue. TCW investor letter
• Neutral Sentiment: Recent quarterly results were strong: revenue increased 18.4% year over year to $2.89 billion and earnings per share reached $2.80, beating the $2.48 consensus estimate. However, investors are placing greater emphasis on forward procedure growth than on the earnings beat.
• Negative Sentiment: U.S. procedure growth slowed in the second quarter. Analysts attributed part of the weakness to Affordable Care Act-related care deferrals, which may be temporary but create uncertainty around near-term demand. U.S. procedure growth report
• Negative Sentiment: Director Gary Guthart sold 10,000 shares for approximately $4 million. The sale was made under a pre-arranged Rule 10b5-1 plan and represented only about 0.8% of his holdings, limiting its significance but potentially weighing modestly on sentiment. Gary Guthart insider sale

Hedge Funds Weigh In On Intuitive Surgical

A number of hedge funds have recently bought and sold shares of ISRG. Prosperity Consulting Group LLC grew its position in shares of Intuitive Surgical by 0.5% in the 3rd quarter. Prosperity Consulting Group LLC now owns 4,033 shares of the medical equipment provider’s stock worth $1,804,000 after acquiring an additional 19 shares in the last quarter. WoodTrust Financial Corp raised its position in shares of Intuitive Surgical by 0.5% during the 4th quarter. WoodTrust Financial Corp now owns 4,180 shares of the medical equipment provider’s stock valued at $2,367,000 after acquiring an additional 20 shares in the last quarter. North Star Investment Management Corp. lifted its stake in Intuitive Surgical by 8.5% during the fourth quarter. North Star Investment Management Corp. now owns 269 shares of the medical equipment provider’s stock worth $152,000 after purchasing an additional 21 shares during the last quarter. Cornerstone Planning Group LLC lifted its stake in Intuitive Surgical by 11.5% during the fourth quarter. Cornerstone Planning Group LLC now owns 203 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 21 shares during the last quarter. Finally, Valeo Financial Advisors LLC boosted its holdings in Intuitive Surgical by 0.4% in the fourth quarter. Valeo Financial Advisors LLC now owns 4,941 shares of the medical equipment provider’s stock worth $2,798,000 after purchasing an additional 21 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.